Related Experiment Video
Updated: Dec 24, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Association between P2RY12 Gene Polymorphisms and IVIG Resistance in Kawasaki Patients
Zhouping Wang1, Yufen Xu2, Huazhong Zhou2
1Department of Cardiology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, China.
Insights
Kawasaki disease (KD) patients with a specific P2RY12 gene variation (rs6809699) show reduced resistance to intravenous immunoglobulin (IVIG) treatment. This finding suggests P2RY12 rs6809699 may serve as a biomarker for predicting IVIG resistance in KD.
Area of Science:
- Genetics
- Immunology
- Pediatrics
Background:
- Kawasaki disease (KD) is a critical condition in children, with intravenous immunoglobulin (IVIG) resistance linked to coronary artery lesions (CAL).
- Purinergic receptor P2Y12 (P2RY12) polymorphisms are associated with KD genetic susceptibility and CAL, but their role in IVIG resistance remains understudied.
Purpose of the Study:
- To investigate the association between P2RY12 polymorphisms and IVIG resistance in Kawasaki disease patients.
- To identify potential genetic biomarkers for predicting IVIG resistance in KD.
Main Methods:
- A case-control study involving 148 IVIG-resistant and 611 IVIG-sensitive KD patients.
- Genotyping of five P2RY12 polymorphisms (rs9859538, rs1491974, rs7637803, rs6809699, rs2046934).
- Statistical analysis, including odds ratios (OR) and confidence intervals (CI), adjusted for age and gender.
Main Results:
- The P2RY12 rs6809699 A>C polymorphism showed a significant association with IVIG sensitivity (e.g., AC vs. AA: adjusted OR=0.48, P=0.011).
- Carriers of the rs6809699 C allele exhibited a protective effect against IVIG resistance (adjusted OR=0.44-0.49).
- Individuals with all five identified protective polymorphisms had significantly decreased IVIG resistance (adjusted OR=0.27, P=0.0006).
Conclusions:
- The P2RY12 rs6809699 polymorphism may act as a predictive biomarker for IVIG resistance in Kawasaki disease patients.
- Identifying patients with specific P2RY12 genotypes could aid in tailoring treatment strategies and managing KD complications.
Abstract:
Children with Kawasaki disease (KD) resistant to intravenous immunoglobulin (IVIG) have a higher incidence of coronary artery lesions (CAL). Despite the association between Purinergic receptor P2Y12 (P2RY12) polymorphism, KD genetic susceptibility, and CAL complications being proved, few studies have assessed the relationship between P2RY12 polymorphisms and IVIG resistance in patients with KD. We recruited 148 KD patients with IVIG resistance and 611 with IVIG sensitivity and selected five P2RY12 polymorphisms: rs9859538, rs1491974, rs7637803, rs6809699, and rs2046934. A significant difference in the genotype distributions between patients was only observed for the rs6809699 A > C polymorphism (AC vs. AA: adjusted odds ratio (OR) = 0.48, 95% confidence interval (CI) = 0.27-0.84, P=0.011; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27-0.83, P=0.0084). After adjusting for age and gender, the carriers of the rs6809699 C allele had OR of 0.44 to 0.49 for IVIG sensitivity (AC vs. AA: adjusted OR = 0.48, 95% confidence interval (CI) = 0.27-0.84, P=0.011; AC/CC vs. AA: adjusted OR = 0.47, 95% CI = 0.27-0.83, P=0.0084) compared to the carriers of a rs6809699 AA genotype, suggesting the protective effect of this SNP against IVIG resistance. Moreover, individuals with all five protective polymorphisms experienced a significantly decreased IVIG resistance compared to that of individuals with up to three protective polymorphisms (adjusted OR = 0.27, 95% CI = 0.13-0.57, P=0.0006). Our results suggest that the P2RY12 rs6809699 polymorphism could be used as a biomarker to predict IVIG resistance in KD patients.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...